Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

2.850 -0.040 (-1.38%)

Official Closing Price Updated: 4:15 PM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

What's going on in today's pre-market session ↗

April 23, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 22, 2026

Via Chartmill

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗

March 05, 2026

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.

Via Stocktwits

Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Altimmune (ALT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗

March 05, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

What 5 Analyst Ratings Have To Say About Altimmune ↗

August 13, 2025

Via Benzinga

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The maker of Wegovy hasn't said its last words just yet.

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗

January 28, 2026

Retail sentiment on major ETFs such as SPY and QQQ turned ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗

January 27, 2026

Altimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk.

Via Stocktwits

Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗

January 23, 2026

Retail sentiment on Stocktwits for SPY and QQQ remained ‘bearish’.

Via Stocktwits

Topics ETFs Government Lawsuit

Uncovering Potential: Altimmune's Earnings Preview ↗

August 11, 2025

Via Benzinga

ALT Stock Rallies 4% — What Does Retail Think? ↗

January 22, 2026

Earlier this month, Altimmune said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide for the treatment of patients with metabolic...

Via Stocktwits

Why Are Investors Looking At Altimmune Stock? ↗

January 05, 2026

Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide.

Via Benzinga

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗

January 05, 2026

The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis.

Via Stocktwits

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗

December 19, 2025

New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests.

Via Stocktwits

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Via Stocktwits

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 10, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday ↗

September 18, 2025

Via Benzinga

Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns

August 19, 2025

San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet...

Via MarketMinute

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results ↗

August 13, 2025

Via Benzinga

Altimmune Q2 FY2025 Earnings Call Transcript ↗

August 12, 2025

Altimmune Q2 FY2025 earnings call transcript

Via Benzinga

Topics Earnings

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 10, 2025

Via Benzinga

Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief ↗

June 28, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts ↗

June 27, 2025

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.

Via Benzinga

Top movers in Thursday's session ↗

June 26, 2025

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 26, 2025

Via Benzinga

Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings ↗

June 26, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.